tive patients NCT00000000 Heparc-0000 Phase 0b Enrolling Multi-dose study to determine the depth of HBsAg reduction in response to ARC-000 in combination with entecavir or tenofovir in HBeAg positive patients NCT00000000 Heparc-0000 Phase 0b Enrolling Multi-dose study to determine the depth of HBsAg reduction in response to ARC-000 in combination with entecavir or tenofovir in HBeAg positive patients NCT00000000 Heparc-0000 